Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis

Although glucocorticoids are the mainstay of treatment in Takayasu arteritis (TA), anti-tumor necrosis factor agents are other treatment options in refractory disease. The onset of TA is generally observed in females of reproductive age. Certolizumab pegol (CZP) lacks a fragment crystallizable region and this gives advantage of minimal transfer through the placenta, which makes CZP a safer option in pregnancy. Although there are case reports and trials about use of infliximab, etanercept, and adalimumab in TA, there are scarce data about use of CZP. In this article, we present three TA cases treated with CZP. While two patients benefited from CZP, one patient was refractory to CZP

Importance of 14-3-3eta, anti-CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis

Background/aim: Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation. The study aimed to assess serum 14-3-3eta, anti-CarP, and anti-Sa in seronegative RA (SNRA) patients who were treatment-naive as well as in healthy subjects. This is the first study in the literature to examine these autoantibodies together in SNRA patients. Materials and methods: Forty-five treatment-naive SNRA patients and 45 healthy subjects were recruited. Drugs change the levels of autoantibodics; therefore, patients who took any medication had been excluded from our study. Anti-carbamylated protein, anti-Sa, and 14-3-3eta were measured by using three different ELISA kits. Results: Median serum concentration of healthy controls in 14-3-3eta was 0.02 (0.02-0.27) ng/mL. Median serum concentration of SNRA patients in 14-3-3eta was 1.00 (0.48-1.28) ng/mL. Data were analyzed with Mann-Whitney U tests; the P-value was <0.001 in 14-3-3eta. Receiver operating characteristic (ROC) curve analysis showed that 14-3-3eta in SNR compared to healthy controls had a significant (P < 0.001) area under the curve (AUC) of 0.90 (95\% confidence interval, 0.83-0.96). At a cutoff of >= 0.33 ng/mL, the ROC curve yielded a sensitivity of 88.9\%, a specificity of 82.2\%, a positive predictive value of 83.3\%, and a negative predictive value of 88.1\%. Conclusion: We found that 14-3-3eta can be used as a diagnostic marker in SNRA

Prevalence, Underlying Factors And Damage Associated With Chronic Persistent Inflammation In Patients With Fmf

Wo

Application Of Auto-Inflammatory Disease Damage Index (Addi) To Patients With Fmf And Related Factors With Damage

Wo